| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
INTRACELLULAR SIGNAL SYSTEMS |
Cardiovascular Research Institute (J.H., R.-H.L., G.L.), National University Medical Institutes, National University of Singapore, Singapore 117597; and Pacific Northwest Research Institute (S.A.M.), Seattle, Washington 98122
Address all correspondence and requests for reprints to: Guodong Li, National University Medical Institutes, MD11 02-01, 10 Medical Drive, Singapore 117597, Singapore. E-mail: . nmiligd{at}nus.edu.sg
This study investigated the possible involvement of a specific caspase(s) (a family of aspartate-specific cysteine proteases) in programmed cell death of islet ß-cells due to sustained GTP depletion. Treatment (up to 48 h) with 3 µg/ml mycophenolic acid (MPA), which specifically depletes intracellular guanine nucleotides, reduced cell-cycle progression from G1 phase into S and G2/M phases (as assessed by flow cytometry) and, subsequently, induced apoptosis of HIT-15 cells (transformed pancreatic ß-cells). The latter was accompanied by a marked increase of caspase-2 activity (+343%) and moderate activation of caspase-9 (+150%) and caspase-3 (+145%). Importantly, only caspase-2 activation preceded induction of apoptosis. There was no change in activity of caspase-1, -4, -5, -6, and -8. Release of the mitochondrial protein cytochrome c into cytosol was also observed at a late stage. Cotreatment of cells with a permeable pan-caspase inhibitor (Z-VAD-FMK) blocked GTP depletion-induced cell death in a dose-dependent manner. A specific caspase-2 inhibitor (Z-VDVAD-FMK), but not a caspase-3 inhibitor (DEVD-CHO), was also capable of restoring cell viability. Interestingly, activation of caspase-2 leads to caspase-3 activation because the caspase-2 inhibitor abrogated caspase-3 activity. Our results indicate that, while activation of multiple caspases are involved in the execution phase of GTP depletion-induced apoptosis, caspase-2 appears to play the major role in the initiation of this program. This study revealed a novel, caspase-2 mediated form of apoptosis that may be consequent to impaired mitogenesis.
This article has been cited by other articles:
![]() |
B. Chaigne-Delalande, G. Guidicelli, L. Couzi, P. Merville, W. Mahfouf, S. Bouchet, M. Molimard, B. Pinson, J.-F. Moreau, and P. Legembre The Immunosuppressor Mycophenolic Acid Kills Activated Lymphocytes by Inducing a Nonclassical Actin-Dependent Necrotic Signal J. Immunol., December 1, 2008; 181(11): 7630 - 7638. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Asfari, S Berta, S Coffy, M Kergoat, C Charon, and A Audet Short-term treatment with mycophenolic acid and tacrolimus is tolerogenic for INS-1 cell clone transplantation and the deleterious effects of the drugs are limited: in vivo and in vitro studies J. Endocrinol., July 1, 2005; 186(1): 213 - 220. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Chen, K. V. Salojin, Q.-S. Mi, M. Grattan, T. C. Meagher, P. Zucker, and T. L. Delovitch Insulin-Like Growth Factor (IGF)-I/IGF-Binding Protein-3 Complex: Therapeutic Efficacy and Mechanism of Protection against Type 1 Diabetes Endocrinology, February 1, 2004; 145(2): 627 - 638. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Maassen, Leen. M. 't Hart, E. van Essen, R. J. Heine, G. Nijpels, R. S. Jahangir Tafrechi, A. K. Raap, G. M.C. Janssen, and H. H.P.J. Lemkes Mitochondrial Diabetes: Molecular Mechanisms and Clinical Presentation Diabetes, February 1, 2004; 53(90001): S103 - 109. [Abstract] [Full Text] |
||||
![]() |
Y.-C. Fu, C.-S. Chi, S.-C. Yin, B. Hwang, Y.-T. Chiu, and S.-L. Hsu Norepinephrine induces apoptosis in neonatal rat endothelial cells via down-regulation of Bcl-2 and activation of {beta}-adrenergic and caspase-2 pathways Cardiovasc Res, January 1, 2004; 61(1): 143 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Maestre, J. Jordan, S. Calvo, J. A. Reig, V. Cena, B. Soria, M. Prentki, and E. Roche Mitochondrial Dysfunction Is Involved in Apoptosis Induced by Serum Withdrawal and Fatty Acids in the {beta}-Cell Line Ins-1 Endocrinology, January 1, 2003; 144(1): 335 - 345. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |